454 related articles for article (PubMed ID: 30420421)
1. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
Saglimbene V; Palmer SC; Ruospo M; Natale P; Maione A; Nicolucci A; Vecchio M; Tognoni G; Craig JC; Pellegrini F; Lucisano G; Hegbrant J; Ariano R; Lamacchia O; Sasso A; Morano S; Filardi T; De Cosmo S; Pugliese G; Procaccini DA; Gesualdo L; Palasciano G; Johnson DW; Tonelli M; Strippoli GFM;
J Am Soc Nephrol; 2018 Dec; 29(12):2890-2899. PubMed ID: 30420421
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
Maione A; Navaneethan SD; Graziano G; Mitchell R; Johnson D; Mann JF; Gao P; Craig JC; Tognoni G; Perkovic V; Nicolucci A; De Cosmo S; Sasso A; Lamacchia O; Cignarelli M; Manfreda VM; Gentile G; Strippoli GF
Nephrol Dial Transplant; 2011 Sep; 26(9):2827-47. PubMed ID: 21372254
[TBL] [Abstract][Full Text] [Related]
6. [Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO).].
Maione A; Nicolucci A; Craig JC; Tognoni G; Moschetta A; Palasciano G; Pugliese G; Procaccini DA; Gesualdo L; Pellegrini F; Strippoli GF
G Ital Nefrol; 2007; 24(5):446-56. PubMed ID: 17886213
[TBL] [Abstract][Full Text] [Related]
7. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
Maione A; Nicolucci A; Craig JC; Tognoni G; Moschetta A; Palasciano G; Pugliese G; Procaccini DA; Gesualdo L; Pellegrini F; Strippoli GF;
J Nephrol; 2007; 20(6):646-55. PubMed ID: 18046666
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
Heerspink HJ
Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
[TBL] [Abstract][Full Text] [Related]
10. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
[TBL] [Abstract][Full Text] [Related]
11. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
St Peter WL; Odum LE; Whaley-Connell AT
Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
Düsing R; Sellers F
Curr Med Res Opin; 2009 Sep; 25(9):2287-301. PubMed ID: 19635044
[TBL] [Abstract][Full Text] [Related]
13. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
16. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
17. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
19. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
[TBL] [Abstract][Full Text] [Related]
20. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
